Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.51 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.45 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.45 |
| ▸ | PNP known ✓ | P00491 | 1/20 | 0.40 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392951 | 0.98 | HSD11B1 (0.53) | HSD11B1CISD1MAOAMAOBPIM1 | |
| SCHEMBL17684427 | 0.80 | HSD11B1 (0.56) | HSD11B1CISD1MAOAMAOBPIM1 | |
| Hydrochloric Acid SCHEMBL6293547 | 0.79 | CYP1A2 (0.50) | MAOAMAOBPIM1PIM2XDH | |
| Hydrochloric Acid SCHEMBL6599594 | 0.79 | IKBKB (0.53) | PIM1PIM2CYP2D6 | |
| Hydrochloric Acid SCHEMBL14721151 | 0.78 | HTR2C (0.43) | CISD1MAOAMAOBPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL2256641 | 0.77 | HTR2C (0.50) | MAOBPIM1PIM2ALDH1A1PNMT | |
| SCHEMBL4853165 | 0.77 | PIM1 (0.46) | MAOAMAOBPIM1PIM2ALDH1A1 | |
| SCHEMBL6398750 | 0.77 | PNMT (0.41) | HSD11B1MAOBPNMT | |
| SCHEMBL28683291 | 0.77 | IKBKB (0.54) | PIM1PIM2CYP2D6 | |
| SCHEMBL27580829 | 0.77 | CYP1A2 (0.51) | MAOAMAOBPIM1PIM2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054724-A1 | BIFUNCTIONAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021086785-A1 | BIFUNCTIONAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | HSD11B1 2121/4885MAOA 257/4885MAOB 173/4885 |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | HSD11B1 1738/4885MAOA 166/4885MAOB 180/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | HSD11B1 941/4885MAOA 3840/4885MAOB 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.